Latterell Venture Partners purchased $1.18M worth of shares in Evoke Pharma, Inc. in August 2018

Sep 08, 2018
Insider Transactions
Background Information
Latterell Venture Partners (LVP) focuses exclusively on investments in large size markets in start-up healthcare companies in the following areas: biotechnology, pharmaceutical, research instrument, biomaterial, medical device and diagnostic ventures. Initial investments range from $50,000 to $10 million, depending on the stage of development of the company's technology or product. LVP expects to support their portfolio companies through financings in the range of $10 million to $20 million per company. The firm leads or co-leads the majority of their investments and typically takes a seat of their portfolio companies' boards of directors.
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.